Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Primary axillary hyperhidrosis is estimated to affect over 10 million people in the U.S.Sofpironium bromide is a retrometabolically designed investigational […]